Generic Name: romosozumab
Brand Name: Evenity
Manufacturer: Amgen Canada Inc.
Therapeutic Area: Osteoporosis, postmenopausal women
Indications: The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.
Manufacturer Requested Reimbursement Criteria1: The treatment of osteoporosis in postmenopausal women with a history of osteoporotic fracture and who are at very high risk for future fracture.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: January 4, 2021
Call for patient/clinician input closed: February 26, 2021
Anticipated Date: February 1, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.